The most important product in Genmab's story is a medicine it does not sell. Daratumumab, the antibody behind Johnson & Johnson's DARZALEX franchise, began in Genmab's laboratories. J&J develops, manufactures and markets it. Genmab receives royalties. In 2025, J&J reported $14.351 billion in worldwide DARZALEX sales, and the checks flowing back to Copenhagen helped make Genmab a $3.720 billion-a-year biotechnology company.
That arrangement once defined Genmab: invent a promising antibody, hand much of the expensive development and commercial work to a pharmaceutical partner, then participate through milestones and royalties. It was a rational model for a small research company. Clinical trials are slow, global launches are costly, and even elegant biology can fail in a patient. A partner spreads the exposure.
But a successful license creates its own itch. The partner controls the medicine, the launch and most of the economics. Genmab now has cash, clinical experience and commercial teams that did not exist when it signed the daratumumab deal in 2012. Its current strategy amounts to a carefully funded escalation: keep the royalty engine running while retaining more ownership of the next generation.
The original trick
Make antibodies behave in new ways
Antibodies are Y-shaped proteins built to recognize a target. Drug developers can redirect that natural precision toward diseased cells. Genmab's expertise lies in engineering the format: deciding what an antibody binds, how many targets it can engage and what happens after it arrives.
Its platform names can sound like a Scandinavian electronic-music festival, but the jobs are distinct. DuoBody creates bispecific antibodies that can bind two targets. That can bring an immune cell close to a cancer cell, as epcoritamab does by engaging CD3 on T cells and CD20 on B cells. HexaBody encourages antibodies to cluster in a six-part ring on a cell surface, strengthening the complement system's attack. DuoHexaBody combines dual targeting with that clustering behavior. HexElect uses a pair of engineered antibodies intended to act most powerfully when a cell presents both selected targets - a two-key system designed to improve selectivity.
This engineering stack is Genmab's moat. A single drug faces patent clocks, rival therapies and clinical surprises. A platform is supposed to be repeatable. Genmab can point to eight approved medicines incorporating its innovation and about 20 clinical-stage compounds. The approved group stretches beyond oncology to Kesimpta for relapsing multiple sclerosis and TEPEZZA for thyroid eye disease, although partners commercialize those products.
The clever part was not simply licensing a blockbuster. It was turning someone else's commercial scale into Genmab's strategic patience.The royalty flywheel
Who pays, who benefits
A business built on shared risk
Genmab's customers are less obvious than those of a conventional software company. Patients and clinicians are the intended beneficiaries. Hospitals, oncology practices and specialty treatment centers administer or prescribe the medicines. The direct commercial counterparties vary: wholesalers and health systems in territories where Genmab sells, and large drug companies where a partner owns the route to market.
The revenue follows those relationships. Partner-marketed drugs such as DARZALEX and Novartis's Kesimpta generate royalties. Collaboration agreements can produce upfront payments, milestones and reimbursement income. EPKINLY, the brand for epcoritamab in the United States, gives Genmab product sales in the U.S. and Japan while AbbVie shares development and commercialization under a 50:50 arrangement. Tivdak, an antibody-drug conjugate for recurrent or metastatic cervical cancer, is partnered 50:50 with Pfizer, with economics varying by market.
Engineer antibodies and move selected programs through discovery and early clinical work.
Share development cost, launch reach and risk in exchange for royalties or divided economics.
Reinvest recurring cash in trials, acquisitions and commercial teams for a larger share of future products.
In 2025, royalties contributed $3.102 billion of Genmab's $3.720 billion revenue. EPKINLY/TEPKINLY worldwide sales were $468 million, up 67 percent from 2024; Genmab booked $379 million of product sales in its U.S. and Japanese territories. This mixture is the point. Royalties provide comparatively high-margin fuel. Direct product sales offer control and more upside, but require sales teams, medical affairs, supply chains and launch spending.
The model also solves a recurring biotech problem: financing ambition without making every clinical decision depend on the next capital raise. Genmab is publicly traded in Copenhagen and, since 2019, through American depositary shares on Nasdaq. Yet its scientific budget is anchored by marketed products rather than financing rounds alone.
The 2025 revenue mix
The expensive second act
From antibody foundry to medicine company
The difference between Genmab and many antibody specialists is no longer just the molecular toolkit. It is the combination of platform, recurring cash flow, partner network and a growing ability to take products further itself. That puts the company in an unusual market position. It competes with large oncology groups such as Roche, AstraZeneca, Amgen and Bristol Myers Squibb; with antibody specialists such as Regeneron and argenx; and with every new modality that can improve on its treatments, from cell therapy to targeted pills. Several of those companies are also collaborators. In biotechnology, the dance card changes by molecule.
Genmab accelerated its ownership strategy through acquisitions. It bought ProfoundBio for roughly $1.8 billion in 2024, adding antibody-drug conjugate capabilities and rinatabart sesutecan, known as Rina-S. In December 2025 it completed the tender offer for Merus in a transaction valued at about $8 billion. The prize asset was petosemtamab, a bispecific antibody in Phase 3 development for head and neck cancer. The Merus deal was financed with $5.5 billion of borrowing plus cash on hand - a scale of commitment that makes the strategic pivot impossible to dismiss as branding.
Ownership brings concentration of another kind. Genmab must integrate teams, service debt, run pivotal studies and prepare launches while continuing to feed the earlier pipeline. A late-stage failure costs more when the company bought the asset and kept the economics. The 2026 expense outlook rose as Genmab invested in late-stage programs and launch readiness. Its own forecast put full-year revenue between $4.065 billion and $4.395 billion, with royalties still supplying most of the total.
Partnerships made Genmab durable. The next question is whether ownership can make it larger without making it ordinary.The integration test
The people inside the platform
A laboratory culture learns to launch
Genmab began in 1999 with about 10 people. Co-founder Jan van de Winkel, an immunotherapy scientist who previously led research and served as chief scientific officer, became CEO in 2010. The organization now has roughly 2,700 employees and operations across North America, Europe and Asia Pacific. Its public culture language revolves around four values: passion for innovation, determination, integrity, and working as one team with respect.
There is an eccentric streak in the corporate vocabulary. Employees are promised an “extra[not]ordinary” experience. The 2030 vision calls for “knock-your-socks-off” antibody medicines. That phrasing is playful by pharmaceutical standards, but the operating priorities beneath it are sober: invest in people, build a differentiated pipeline, bring owned medicines to patients and become a fully integrated biotech.
The customers will not grade the wordplay. A hematologist choosing among crowded lymphoma options needs evidence on survival, safety, sequencing and convenience. A hospital needs reliable supply and reimbursement support. A patient needs more time, a better response or fewer punishing tradeoffs. Genmab's antibodies are tools for those outcomes, not outcomes by themselves.
Recent results show both the inheritance and the direction. J&J reported $4.207 billion in DARZALEX sales for the second quarter of 2026. In July, European regulators approved a TEPKINLY combination for adults with relapsed or refractory follicular lymphoma. A month earlier, a Phase 3 epcoritamab combination study in relapsed or refractory diffuse large B-cell lymphoma met its progression-free-survival endpoint. The old royalty engine is still accelerating while the newer commercial portfolio gathers indications.
Where Genmab fits now
Genmab sits between categories, which is usually where an interesting company is found. It is too commercial to be described as a research boutique, too platform-driven to look like a conventional pharmaceutical conglomerate, and too dependent on partner royalties to claim complete independence. Its advantage is that it does not have to choose one identity all at once.
For partners, Genmab offers antibody formats, biological expertise and a record of medicines that survived the long route to approval. For clinicians and patients, it offers approved therapies and an oncology-heavy pipeline. For investors, it offers a mature royalty base attached to a riskier reinvestment story. The strategic lesson is simple enough to steal: build a dependable engine before asking it to finance the leap.
That leap is now underway. DARZALEX proved Genmab could invent a molecule worthy of global scale. EPKINLY and Tivdak began teaching it how to share the selling. ProfoundBio and Merus added assets it has more reason to carry itself. The next chapter will be written in clinical readouts, regulatory decisions and launches - the unglamorous scorecard by which a medicine cabinet is actually filled.